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QOL Metric O-GVHD Estimate P NIH Eye score Estimate P
FACT-G No 0* 0.006 0 0* 0.05
ˇ
Yes -2.1 1 -0.7 0.40
Abstracts / Biol Blood Marrow Transplant 20 (2014) S257eS285 S269may be independent of whether the phenotype of the donor
immune cells is malignant and that GvHD and GvL may be
more a quantitative than qualitative effect.2 or 3 -2.5 0.01
FACT-TOI No 0* <0.001 0 0* 0.03
ˇ
Yes -2.6 1 -1.5 0.04
2 or 3 -2.4 0.01
FACT-BMT No 0* 0.002 0 0* 0.08
ˇ
Yes -3.0 1 -1.3 0.19
2 or 3 -3 0.03
Lee Score** No 0* <0.001 0 0* 0.01
ˇ
Yes 2.8 1 1.7 0.01
2 or 3 2.1 0.02
ˇ
overall P value; *Estimate 0-reference category; **Lee symptom score-eye
component excluded418
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Background: Ocular GVHD (o-GVHD) is a known manifes-
tation of chronic GVHD (cGVHD). There are no prospective
studies of factors associated with o-GVHD or its impact on
quality of life (QOL). We analyzed the above endpoints using
the cGVHD consortium database; a prospective multi-center
longitudinal observational study.
Methods: The study included patients with cGVHD requiring
systemic treatment and enrolled within 3 months of diag-
nosis. O-GVHD was deﬁned as NIH eye score > 0 and patient
reported symptoms (> 1 on 0-10 eye related symptoms or
>20 on Lee symptom eye score). Variables associated with o-
GVHD at enrollment and subsequent new onset o-GVHD, and
the associations with QOL were studied.
Results: The cumulative incidence of o-GVHD at 2 y after
cGVHD diagnosis was 58%. Of the 290 patients with o-GVHD,
117 (40%) had it within 3 months of cGVHD diagnosis (“early
o-GVHD”). Chronic GVHD characteristics associated with
early o-GVHD included: more severe global cGVHD
(P<0.001), and greater severity of mouth (P¼0.001), esoph-
agus (P¼0.002), and liver (P<0.001) involvement. In a
multivariable analysis, female sex (OR 2.0, P¼0.01) and
higher prednisone dose at enrollment (P¼0.04) were asso-
ciated with o-GVHD. Early o-GVHD was not associated with
subsequent non-relapse mortality (HR 1.2, P¼0.53) or sur-
vival (HR 1.1, P¼0.85).
Late o-GVHD (new onset > 3 months after cGVHD diag-
nosis) occurred in 68 patients. The cumulative incidence of
late o-GVHD at 2-y post enrollment was 39%. Inmultivariable
modeling, presence of prior grade I-IV aGVHD (HR 1.8,
P¼0.03) was associated with shorter time to late o-GVHD,
while female donor into male recipient (HR 0.5, P¼0.05) was
associated with longer time to late o-GVHD onset.
The Table shows the association of o-GVHD with QOL
metrics, using all available visit data adjusted for center
effect, months since enrollment, platelet count, NIH
severity, bilirubin, prior aGVHD, and overlap vs. classic
cGVHD.
Conclusion: This large multicenter, prospective study shows
that o-GVHD affects 58% of patients at 2 y after a diagnosis of
cGVHD and is statistically associated with worse QOL and
more cGVHD symptoms compared to patients with cGVHD
without ocular involvement. Since o-GVHD may be due to
permanent destruction of lacrimal glands, prophylactic or
pre-emptive clinical trial strategies prior to onset ofirreversible dry eye syndrome are needed. Women, patients
on higher doses of prednisone, and those with a history of
acute GVHD seem to be at higher risk for o-GVHD.419
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Graft vs. host (GVH) effect mediated by donor T cells are
responsible for a signiﬁcant measure of therapeutic beneﬁt
as well as toxicity observed following stem cell trans-
plantation (SCT) between HLA-identical donors and re-
cipients. Donor T cell-mediated GVH effects may be
inﬂuenced by the aggregate alloreactivity to minor histo-
compatibility antigens (mHA) presented by the HLA in each
donor-recipient pair (DRP). The cumulative mHA variation in
each DRPmay thus be regarded as the alloreactivity potential
(AP) of that pair. To estimate AP in DRP, whole exome
sequencing (WES) of 4 matched-related (MRD) and 5 unre-
lated (URD) pairs was performed and revealed extensive
coding variation between them. To quantify the contribution
of exome sequence variation to AP, data from each DRP was
ﬁltered to isolate non-synonymous single nucleotide poly-
morphisms (SNP) in the GVH direction (polymorphisms
present in recipient and absent in donor). Logically, the SNP
involved in encoding peptides presented on the HLA in each
DRP will contribute to the AP in that pair. To identify these
peptides, the nucleotide sequence ﬂanking all of the several
thousand SNP in each DRP was obtained with the ANNOVAR
software package. All possible resulting nonameric-peptides
were interrogated in-silico for their likelihood to be pre-
sented by each of the 6 HLA class I molecules in individual
DRP, using the Immune-Epitope Database (IEDB) SMM al-
gorithm. The IEDB-SMM algorithm predicted between
1,043,514 and 366,426 peptides/DRP (w 18 peptides/SNP).
Peptide-HLA binding afﬁnity estimate was reported as an
IC50 value, which when <500 nM, predicts that peptides
Figure 1. Comparison of total number of SNP (WES) in each DRP, in silico derived nona-peptides with strong binding (IC50 <50 nm) and strong-week binding (IC50
<500 nM).
Figure 2. IC50 values of peptide-HLA complexes for MRD (red) URD (blue) for
IC50 < 500nm. Data for a single allele presented. Peptides below the black line
are strong binding (IC50 <50 nm).
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1.2% of all the above peptides were categorized as presented
by the HLA class I molecules in the DRP examined, with a
smaller fraction of these peptides being strong binders (IC50
<50nM). (Fig 1) In our small cohort, MRD presented a me-
dian 3% (range 1-10) of all the predicted peptides, compared
with 13.5% (4-20) for the URD. Further, plotting the IC50
values of the presented-peptides in each DRP, demonstrated
a continuum of binding afﬁnities (Fig 2) as opposed to
discrete sets of values taken on by different peptides,
implying a certain degree of plasticity in this system.
Computing the area under the curve for these data to account
for both number of and binding afﬁnity of peptide-HLA
complexes, demonstrated amarked difference betweenMRD
(1x10
ˇ
6 nM.Peptide-HLA) and URD (8x10
ˇ
6). Our data dem-
onstrates that a marked difference is evident between URD
and MRD when WES is used to predict potential protein-
coding differences - estimating an HLA-speciﬁc AP in unique
DRP. This represents a paradigm shift away from looking for
unique mHA to predict likelihood of developing GVH phe-
nomenon in a population-basedmanner, andmay eventually
better deﬁne GVHD risk in HLA matched DRP.420
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Graft versus host disease (GvHD) is an often fatal complica-
tion of allogeneic tissue transplantation. While typical tar-
gets of GvHD include the skin, lung, liver and GI tract, a
myriad of other organ systems are being identiﬁed as targets
of this disease. Although the neurologic complications that
occur during hematopoietic stem cell transplant (HCT) have
been extensively described (Siegal et al., BBMT, 2007), little
information is available about the incidence and biology of
GvHD in the central nervous system (CNS). Case reports have
shown that the CNS can be a target of GvHD and show high
mortality rates when involved (Saad et al., JCO, 2009). A
recent study found both pathologic and behavioral conse-
quences of CNS-GVHD in a mouse model (Hartrampf et al.,
Blood, 2013). Further study of CNS-GvHD is needed to better
understand this entity that is often difﬁcult to access
clinically.
Non-human primates have been shown to closely model
humans during and after HCT. To investigate the prevalence
of CNS manifestations of acute GvHD such a model, we
conducted a HCT study with the following Transplant/GvHD
prophylaxis regimens: 1) Autologous/None 2) Allogeneic/
